Quoin Pharmaceuticals, Ltd.

Business Summary

PARTI Company Overview We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases for which there are currently either no approved or very limited treatments or cures. Our lead product, QRX003, is under clinical development as a potential treatment for Netherton Syndrome (NS), a rare hereditary genetic disease. QRX003 is entering pivotal registrational clinical testing under an open In...

Next Earnings

Q2 FY2026 — expected 2026-08-15

Key Facts from Earnings Calls

Annual Reports (10-K)

Quarterly Reports (10-Q)

Recent Current Reports (8-K)

264 total filings indexed. 241 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

Company Identity

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API: